At the end of the latest market close, BioCryst Pharmaceuticals Inc. (BCRX) was valued at $10.12. In that particular session, Stock kicked-off at the price of $10.17 while reaching the peak value of $10.605 and lowest value recorded on the day was $10.05. The stock current value is $10.41.
Recently in News on April 7, 2021, BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference. BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
BioCryst Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $14.24 on 03/22/21, with the lowest value was $7.27 for the same time period, recorded on 01/05/21.
BioCryst Pharmaceuticals Inc. (BCRX) full year performance was 407.80%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioCryst Pharmaceuticals Inc. shares are logging -26.90% during the 52-week period from high price, and 445.03% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.91 and $14.24.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2845890 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the BioCryst Pharmaceuticals Inc. (BCRX) recorded performance in the market was 39.73%, having the revenues showcasing 41.25% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.89B, as it employees total of 246 workers.
BioCryst Pharmaceuticals Inc. (BCRX) in the eye of market guru’s
During the last month, 0 analysts gave the BioCryst Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.89, with a change in the price was noted +6.33. In a similar fashion, BioCryst Pharmaceuticals Inc. posted a movement of +155.15% for the period of last 100 days, recording 7,522,401 in trading volumes.
BioCryst Pharmaceuticals Inc. (BCRX): Stocks Technical analysis and Trends
Raw Stochastic average of BioCryst Pharmaceuticals Inc. in the period of last 50 days is set at 34.75%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 22.47%. In the last 20 days, the company’s Stochastic %K was 18.22% and its Stochastic %D was recorded 15.77%.
If we look into the earlier routines of BioCryst Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 39.73%. Additionally, trading for the stock in the period of the last six months notably improved by 185.60%, alongside a boost of 407.80% for the period of the last 12 months. The shares increased approximately by 4.20% in the 7-day charts and went up by -6.17% in the period of the last 30 days. Common stock shares were driven by 41.25% during last recorded quarter.